Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.72 |
| ▸ | BACE2 | Q9Y5Z0 | 15/20 | 0.72 |
| ▸ | APP | P05067 | 13/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | CTSD | P07339 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16857605 | 0.95 | BACE1 (0.70) | BACE1BACE2APPCYP2D6CYP3A4 | |
| SCHEMBL16857653 | 0.95 | BACE1 (0.70) | BACE1BACE2APPCYP2D6CYP3A4 | |
| SCHEMBL16857594 | 0.90 | BACE1 (0.65) | BACE1BACE2APPCYP2D6CYP3A4 | |
| SCHEMBL16857611 | 0.90 | BACE1 (0.65) | BACE1BACE2APPCYP2D6CYP3A4 | |
| SCHEMBL16857633 | 0.89 | BACE1 (0.73) | BACE1BACE2APPCYP2D6CYP3A4 | |
| SCHEMBL16857656 | 0.89 | BACE1 (0.73) | BACE1BACE2APPCYP2D6CYP3A4 | |
| SCHEMBL16857596 | 0.89 | BACE1 (0.65) | BACE1BACE2APPCYP2D6CYP3A4 | |
| SCHEMBL16857646 | 0.89 | BACE1 (0.65) | BACE1BACE2APPCYP2D6CYP3A4 | |
| SCHEMBL16857647 | 0.88 | BACE1 (0.64) | BACE1BACE2APPCYP2D6CYP3A4 | |
| SCHEMBL16857648 | 0.88 | BACE1 (0.64) | BACE1BACE2APPCYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2663559-B1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-07-01 | — | — | EP | claimed |